These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 23613597)

  • 21. Fentanyl pectin nasal spray for breakthrough cancer pain.
    Torres LM; Trinidad JM; Calderón E; Benitez D; Perelman M
    Int J Palliat Nurs; 2015 Mar; 21(3):114-6. PubMed ID: 25815759
    [No Abstract]   [Full Text] [Related]  

  • 22. WITHDRAWN: Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD004311. PubMed ID: 26275024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 'Old' and 'new' drugs for the treatment of cancer pain.
    Santini D; Lanzetta G; Dell'Aquila E; Vincenzi B; Venditti O; Russano M; Papapietro N; Denaro V; Tonini G; Ripamonti C
    Expert Opin Pharmacother; 2013 Mar; 14(4):425-33. PubMed ID: 23438421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fentanyl nasal spray (Lazanda) for pain.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):99-100. PubMed ID: 22173454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cancer breakthrough pain. Indications for rapidly effective opioids].
    Kessler J; Bardenheuer HJ
    Anaesthesist; 2011 Jul; 60(7):674-82. PubMed ID: 21491140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
    Mercadante S
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):9-13. PubMed ID: 25359295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group.
    Mercadante S; Marchetti P; Cuomo A; Mammucari M; Caraceni A;
    Support Care Cancer; 2016 Feb; 24(2):961-968. PubMed ID: 26438145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fentanyl for breakthrough pain: a systematic review.
    Davis MP
    Expert Rev Neurother; 2011 Aug; 11(8):1197-216. PubMed ID: 21797660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
    Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
    J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
    Mercadante S; Prestia G; Adile C; Casuccio A
    J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
    Am J Hosp Palliat Care; 2005; 22(3):228-32. PubMed ID: 15909786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence-based treatment of cancer-related breakthrough pain with opioids.
    Zeppetella G
    J Natl Compr Canc Netw; 2013 Mar; 11 Suppl 1():S37-43. PubMed ID: 23520185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication.
    Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ; Sanz A
    Drugs R D; 2018 Jun; 18(2):119-128. PubMed ID: 29572732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are there cost benefits to fentanyl for breakthrough pain?
    Davis MP
    J Pain Symptom Manage; 2012 Sep; 44(3):e1-2. PubMed ID: 22939453
    [No Abstract]   [Full Text] [Related]  

  • 35. The pharmacoeconomics of breakthrough cancer pain.
    Kuo KL; Saokaew S; Stenehjem DD
    J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):167-75. PubMed ID: 23688496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral transmucosal fentanyl: new preparation. For breakthrough cancer pain when morphine fails.
    Prescrire Int; 2002 Aug; 11(60):106-7. PubMed ID: 12199262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of intravenous fentanyl against morphine tolerance in breakthrough cancer pain: a case series and literature review.
    Hwang IC; Bruera E; Park SM
    Am J Hosp Palliat Care; 2014 Feb; 31(1):109-11. PubMed ID: 23345613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain.
    Passik SD; Narayana A; Yang R
    Pain Med; 2014 Aug; 15(8):1365-72. PubMed ID: 24666664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
    Alberts DS; Smith CC; Parikh N; Rauck RL
    Pain Manag; 2016 Oct; 6(5):427-34. PubMed ID: 27020837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fentanyl buccal tablet (Fentora) for breakthrough pain.
    Med Lett Drugs Ther; 2007 Sep; 49(1270):78-9. PubMed ID: 17878889
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.